MARKET

BIVI

BIVI

BioVie
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.05
-0.54
-3.46%
Closed 16:00 07/29 EDT
OPEN
15.94
PREV CLOSE
15.59
HIGH
15.94
LOW
14.90
VOLUME
13.52K
TURNOVER
--
52 WEEK HIGH
46.10
52 WEEK LOW
7.50
MARKET CAP
336.12M
P/E (TTM)
-1.2683
1D
5D
1M
3M
1Y
5Y
BioVie Highlights Presentation Of Data On NE3107 As Treatment For Alzheimer's Disease
BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of liver disease, neurodegenerative disease and certain cancers, announced today that a poster by Christopher L Reading, PhD,
Benzinga · 2d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Benzinga · 2d ago
BioVie Presents Data Supporting use of NE3107 in the Treatment of Alzheimer’s Disease at 2021 Alzheimer’s Association International Conference
NE3107 Is the First Potentially Disease Modifying, Anti-Inflammatory Insulin Sensitizer Therapy In A Pivotal Phase 3 TrialSANTA MONICA, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., a clinical-stage company developing innovative drug therapies for...
GlobeNewswire · 2d ago
BRIEF-BioVie To Present Rationale For Use Of NE3107 For Treatment Of Alzheimer’s
reuters.com · 07/22 12:59
BioVie to Present Rationale for use of NE3107 for the Treatment of Alzheimer’s Disease at 2021 Alzheimer’s Association International Conference
Trial will be first Phase 3 disease modifying anti-inflammatory insulin sensitizer therapy in Alzheimer’s diseaseSANTA MONICA, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., a clinical-stage company developing innovative drug therapies for the trea...
GlobeNewswire · 07/22 12:00
BioVie highlights Alzheimer’s disease treatment's potential ahead of upcoming late-stage trial
BioVie (BIVI) highlights article summarizing the scientific rationale for the company’s upcoming late-stage trial of NE3107 in Alzheimer’s disease published in Neurodegenerative Disease Management.The article details rationale for an anti-inflammatory
Seekingalpha · 07/16 12:14
BRIEF-Basis For BioVie’S Phase 3 Clinical Trial Of NE3107 Published In Neurodegenerative Disease Management
reuters.com · 07/16 12:07
Basis for BioVie’s Phase 3 Clinical Trial of NE3107 in the Treatment of Alzheimer’s Disease Published in Neurodegenerative Disease Management
Pivotal Phase 3 Trial of NE3107 Expected to Commence in Summer 2021SANTA MONICA, Calif., July 16, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of liver disease, neurodegenerative dise...
GlobeNewswire · 07/16 12:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BIVI. Analyze the recent business situations of BioVie through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BIVI stock price target is 50.00 with a high estimate of 50.00 and a low estimate of 50.00.
EPS
Institutional Holdings
Institutions: 13
Institutional Holdings: 319.10K
% Owned: 1.43%
Shares Outstanding: 22.33M
TypeInstitutionsShares
Increased
1
1
New
5
140.96K
Decreased
5
23.32K
Sold Out
2
27.80K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.49%
Pharmaceuticals & Medical Research
-0.31%
Key Executives
Chairman/Director
Terren Peizer
President/Chief Executive Officer
Cuong Do
Chief Financial Officer/Secretary
J. Wendy Kim
Chief Operating Officer
Jonathan Adams
Chief Scientific Officer
Penelope Markham
Other
Patrick Yeramian
Director
Richard Berman
Director
Steven Gorlin
Director
Robert Hariri
Director
Rajah Menon
Director
Sigmund Rogich
Independent Director
Hari Kumar
Independent Director
James Lang
Independent Director
Michael Sherman
Independent Director
Mina Sooch
No Data
About BIVI
BioVie Inc. clinical-stage company pursuing the discovery, development, and commercialization of drug therapies for liver disease. The Company is focused on developing and commercializing BIV201 (continuous infusion terlipressin) an approach to the treatment of ascites due to chronic liver cirrhosis. BIV201 also has an Orphan Drug designation for the treatment of hepatorenal syndrome (HRS). The Company is developing BIV201, a treatment option for patients suffering from ascites and other life-threatening complications of advanced liver cirrhosis caused by hepatitis, nonalcoholic steatohepatitis (NASH) and alcoholism. The Company is also engaged in developing NE3107, an ERK inhibitor that selectively reduces neuroinflammation and insulin resistance.

Webull offers kinds of BioVie Inc stock information, including NASDAQ:BIVI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIVI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BIVI stock methods without spending real money on the virtual paper trading platform.